EGA
CARM

Eagle Global Advisors’s Carisma Therapeutics CARM Stock Holding History

Eagle Global Advisors’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,327
Closed -$58K – 441
2017
Q1 		$58K Buy
1,327
+247
+23% +$10.3K ﹤0.01% 383
2016
Q4 		$41K Buy
+1,080
New +$47.6K ﹤0.01% 370

Other funds holding CARM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Eagle Global Advisors's CARM Position: Q2 2017 in Review

Eagle Global Advisors sold out of Carisma Therapeutics (CARM) in Q2 2017, closing a stake of 1,327 shares — an estimated $58K sold.

Eagle Global Advisors first reported a position in CARM in Q4 2016 and held it in 2 quarters. The position peaked at $58K in Q1 2017. 26 funds tracked by Wall St. Rank hold CARM as of Q2 2017.

  • Eagle Global Advisors reported no remaining Carisma Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Eagle Global Advisors sold 1,327 Carisma Therapeutics shares in Q2 2017, an estimated $58K.
  • Eagle Global Advisors first reported a position in Carisma Therapeutics in Q4 2016 and held it in 2 quarters.
  • Eagle Global Advisors's Carisma Therapeutics position peaked at $58K in Q1 2017.
  • 26 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2017.

Based on Eagle Global Advisors's 13F filing for Q2 2017, filed 27 Jul 2017.